<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">epidemiology</journal-id><journal-title-group><journal-title xml:lang="ru">Эпидемиология и Вакцинопрофилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Epidemiology and Vaccinal Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2073-3046</issn><issn pub-type="epub">2619-0494</issn><publisher><publisher-name>«Numicom» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31631/2073-3046-2021-20-6-88-99</article-id><article-id custom-type="elpub" pub-id-type="custom">epidemiology-1404</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>На путях к индивидуализации вакцинации: значение возраста и пола</article-title><trans-title-group xml:lang="en"><trans-title>On the Road to Individualization of Vaccination: the Significance of Age and Sex</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9958-8104</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каральник</surname><given-names>Б. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Karalnik</surname><given-names>B. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Борис Вольфович Каральник  – д. м. н. (микробиология), профессор (иммунология), главный научный сотрудник, Общественное Объединение «Научно-медицинское общество»</p><p>Республика КазахстанТел. +7 27 303 10 89, +7 (705) 302-86-78</p></bio><bio xml:lang="en"><p>Boris V. Karalnik – Dr. Sci. (Med.) (microbiology), professor (immunology), chief researcher Public Association «Medical Scientific Society»</p><p>Republic of KazakhstanTel. +7 27 303 10 89, +7 (705) 302-86-78</p></bio><email xlink:type="simple">bvkaralnik@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Общественное Объединение «Научно-медицинское общество»; Научный центр гигиены и эпидемиологии им. Х. Жуматова, филиал Национального Центра общественного здравоохранения</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Public Association «Medical Scientific Society»;  Kh. Zhumatov Scientific Center for Hygiene and Epidemiology, branch of the National Center for Public Health</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>06</day><month>01</month><year>2022</year></pub-date><volume>20</volume><issue>6</issue><fpage>88</fpage><lpage>99</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каральник Б.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Каральник Б.В.</copyright-holder><copyright-holder xml:lang="en">Karalnik B.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.epidemvac.ru/jour/article/view/1404">https://www.epidemvac.ru/jour/article/view/1404</self-uri><abstract><p>Актуальность. Высокая вариабельность защиты от инфекций, контролируемых вакцинацией, включая COVID-19, является одной из актуальных проблем инфектологии. Цель. На основе анализа результатов научных публикаций и отчетов проанализирована роль факторов возраста и пола, их взаимодействия и основных механизмов в иммунном ответе на вакцины, в совершенствовании вакцин и схем вакцинации. Заключение. Показано, что вакцинопрофилактика всегда развивалась в направлении индивидуализации, проходя этапы определения целевых групп и разработки схем иммунизации различных групп. Проанализированы полученные в последние десятилетия важные данные о значении генетических и внешних факторов, в частности, возраста и пола, в вариабельности ответа на вакцины. Анализ роли таких факторов выполнен также для коронавирусных вакцин. Обсуждены необходимость и возможности очередных действий, которые могут обеспечить оптимальные ответы различных людей на вакцинацию.</p></abstract><trans-abstract xml:lang="en"><p>Relevance. The high variability of protection against vaccine-controlled infections, including COVID-19, is one of the actual problem of infectology. Aim. Based on the results of scientific publications and reports, the role of age and sex factors, their interactions and the main mechanisms in the immune response to vaccines, in the improvement of vaccines and vaccination regimens, has been analyzed. Conclusion. It has been shown that vaccine prophylaxis has always developed in the direction of individualization, going through the stages of defining target groups and developing immunization schemes for various groups. The important data obtained in recent decades on the importance of genetic and external factors, in particular, age and sex, in the variability of response to vaccines are analyzed. Analysis of the role of such factors has also been performed for coronavirus vaccines. The necessity and possibilities of next steps that can provide optimal responses of different people to vaccination were discussed.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>вакцинация</kwd><kwd>вариабельность</kwd><kwd>эффективность</kwd><kwd>влияние возраста и пола</kwd><kwd>роль врожденного и адаптивного иммунитета</kwd><kwd>сопутствующие заболевания</kwd><kwd>беременность</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>vaccination</kwd><kwd>variability</kwd><kwd>efficiency</kwd><kwd>influence of age and sex</kwd><kwd>the role of innate and adaptive immunity</kwd><kwd>concomitant diseases</kwd><kwd>pregnancy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Jenner E An Inquiry Into the Causes and Effects of the Variolae Vaccinae, A Disease Discovered in Some of the Western Countries of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox - London.1798</mixed-citation><mixed-citation xml:lang="en">Jenner E An Inquiry Into the Causes and Effects of the Variolae Vaccinae, A Disease Discovered in Some of the Western Countries of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox - London.1798</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Inf. Dis. 2014;59(1):144. https:doi.org/10.1093/cid/cit816</mixed-citation><mixed-citation xml:lang="en">Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Inf. Dis. 2014;59(1):144. https:doi.org/10.1093/cid/cit816</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каральник Б. В, Рамазанова Б. А. Защита от инфекций групп риска вакцинацией. На чем основаны правила вакцинации групп риска? Методические рекомендации. Алматы. Научное издание. 2018. 44 с.</mixed-citation><mixed-citation xml:lang="en">Karalnik BV, Ramazanova BA Zashchita ot infektsiy grupp riska vaktsinatsiyey. Na chem osnovany pravila vaktsinatsii grupp riska? Metodicheskiye rekomendatsii Almaty: Nauchnoye izdaniye Almaty. 2018:44 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Poland GA, Kennedy RB, McKinney BA, et al. Vaccinomics, adversomics, and the immune response network theory: Individualized vaccinology in the 21st century Seminars in Immunology 2013;25(2):89–103 https:doi.0rg/10.1016/j.smim.2013.04.007</mixed-citation><mixed-citation xml:lang="en">Poland GA, Kennedy RB, McKinney BA, et al. Vaccinomics, adversomics, and the immune response network theory: Individualized vaccinology in the 21st century Seminars in Immunology 2013;25(2):89–103 https:doi.0rg/10.1016/j.smim.2013.04.007</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Qin L, Li X, Shi J, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. Med. Virol.2020;92(11):2684–2692. https:doi.org/10.1002/jmv.26137</mixed-citation><mixed-citation xml:lang="en">Qin L, Li X, Shi J, et al. Gendered effects on inflammation reaction and outcome of COVID-19 patients in Wuhan. Med. Virol.2020;92(11):2684–2692. https:doi.org/10.1002/jmv.26137</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wtinberger B, Heinder-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis.2008;46(7):1078–84</mixed-citation><mixed-citation xml:lang="en">Wtinberger B, Heinder-Brandstetter D, Schwanninger A, et al. Biology of immune responses to vaccines in elderly persons. Clin. Infect. Dis.2008;46(7):1078–84</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chen WH, Kozlovsky BF, Effros RB, et al. Vaccination in the elderly: an immunological perspective Trends Immunol. 2009;30(7):351–9.</mixed-citation><mixed-citation xml:lang="en">Chen WH, Kozlovsky BF, Effros RB, et al. Vaccination in the elderly: an immunological perspective Trends Immunol. 2009;30(7):351–9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Williamson EJ, Walker AJ, Goldacre B, et al. Factors associated with COVID-19-related death using Open SAFELY. Nature.2020;584:430–436.</mixed-citation><mixed-citation xml:lang="en">Williamson EJ, Walker AJ, Goldacre B, et al. Factors associated with COVID-19-related death using Open SAFELY. Nature.2020;584:430–436.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Senden Th.F Response to intradermal hepatitis B vaccination: differences between males and females? Vaccine. 1990;8(6):612–613. https:doi.org/10.1016/0264-410X(90)90037-m</mixed-citation><mixed-citation xml:lang="en">Senden Th.F Response to intradermal hepatitis B vaccination: differences between males and females? Vaccine. 1990;8(6):612–613. https: doi.org/10.1016/0264-410X(90)90037-m</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kiecolt-Glaser JK, Glaser R, Gravenstein S, et al. Chronic stress alters the immune response to influenza virus vaccine in older adults. PNAS 1996;93(7):3043–3047. https:doi.0rg/10.1073/pnas.937.3043</mixed-citation><mixed-citation xml:lang="en">Kiecolt-Glaser JK, Glaser R, Gravenstein S, et al. Chronic stress alters the immune response to influenza virus vaccine in older adults. PNAS 1996;93(7):3043–3047. https:doi.0rg/10.1073/pnas.937.3043</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Giefing-Kroll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell.2015;14:309–321. doi:10.1111/acel.12326.</mixed-citation><mixed-citation xml:lang="en">Giefing-Kroll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell.2015;14:309–321. doi:10.1111/acel.12326.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Edelman R, Deming ME, Toapanta FR, et al. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immunity and Ageing,2020;17::9. doi:10.1186/s12979-020-00179</mixed-citation><mixed-citation xml:lang="en">Edelman R, Deming ME, Toapanta FR, et al. The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immunity and Ageing,2020;17::9. doi:10.1186/s12979-020-00179</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Marquez EJ, Chung Ch-h, Marches R, et al. Sexual-dimorphism in human immune system aging. Nature Communications. 2020;11(1):751. doi:10.1038/s41467-020-14396-9.</mixed-citation><mixed-citation xml:lang="en">Marquez EJ, Chung Ch-h, Marches R, et al. Sexual-dimorphism in human immune system aging. Nature Communications. 2020;11(1):751. doi:10.1038/s41467-020-14396-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Piasecka B, Duffy D, Urrutia A, et al. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges PNAS.2018;115(3):E488–E497. https:doi.org/10.1073/pnas.1714765115</mixed-citation><mixed-citation xml:lang="en">Piasecka B, Duffy D, Urrutia A, et al. Distinctive roles of age, sex, and genetics in shaping transcriptional variation of human immune responses to microbial challenges PNAS.2018;115(3):E488–E497. https:doi.org/10.1073/pnas.1714765115</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gensous N, Franceschi C, Blombtug BB, et al. Responders and non-responders to influenza vaccination: a DNA methylation approach on blood cells. Exp.Gerontology. 2018;105:94–100.</mixed-citation><mixed-citation xml:lang="en">Gensous N, Franceschi C, Blombtug BB, et al. Responders and non-responders to influenza vaccination: a DNA methylation approach on blood cells. Exp.Gerontology. 2018;105:94–100.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Paul WE. Bridging innate and adaptivei mmunity Cell. 2011:147(6):1212–1215 doi:101016/j.cell.2011.11.036</mixed-citation><mixed-citation xml:lang="en">Paul WE. Bridging innate and adaptivei mmunity Cell. 2011:147(6):1212–1215 doi:101016/j.cell.2011.11.036</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Seyda M, Elkhal A, Quante M, et al. T cells going innate. Trends Immunol.2016;37(8):546–556. doi:10.1016/j.it.2016.06.004</mixed-citation><mixed-citation xml:lang="en">Seyda M, Elkhal A, Quante M, et al. T cells going innate. Trends Immunol.2016;37(8):546–556. doi:10.1016/j.it.2016.06.004</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira BI, Akbar AN. Convergence of innate and adaptive immunity during human aging. Front. Immunol. 2016; Nov 4;7:445. https:doi.org/10.3389/fimmu.2016.00445.</mixed-citation><mixed-citation xml:lang="en">Pereira BI, Akbar AN. Convergence of innate and adaptive immunity during human aging. Front. Immunol. 2016; Nov 4;7:445. https:doi.org/10.3389/fimmu.2016.00445.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Deshpande S. Effect of biological sex and age on universal influenza vaccine induced immunity in mice. Available at: https:jscholarship.library.jhu.edu/handle/1774.2/62647</mixed-citation><mixed-citation xml:lang="en">Deshpande S. Effect of biological sex and age on universal influenza vaccine induced immunity in mice. Available at: https:jscholarship.library.jhu.edu/handle/1774.2/62647</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Beeslaar J, Peyrani P, Absalon J, et al. Sex, age, and race effects on immunogenicity of MenB-FHbp, a bivalent meningococcal B vaccine: pooled evaluation of clinical trial data. Inf. Dis. and Therapy.2020;9:625–639. https:doi.org/10.1007/s40121-020-00322-5</mixed-citation><mixed-citation xml:lang="en">Beeslaar J, Peyrani P, Absalon J, et al. Sex, age, and race effects on immunogenicity of MenB-FHbp, a bivalent meningococcal B vaccine: pooled evaluation of clinical trial data. Inf. Dis. and Therapy.2020;9:625–639. https:doi.org/10.1007/s40121-020-00322-5</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ursin RL, Liu H, Powell HR, et al. Differential antibody recognition of H3N2 vaccine and seasonal influenza virus strains based on age, vaccine status, and sex in the 2017–2018 season. J. Inf. Dis.2020;222(8):1371–1382. https://doi.org/10.1093/infdis/jiaa289</mixed-citation><mixed-citation xml:lang="en">Ursin RL, Liu H, Powell HR, et al. Differential antibody recognition of H3N2 vaccine and seasonal influenza virus strains based on age, vaccine status, and sex in the 2017–2018 season. J. Inf. Dis.2020;222(8):1371–1382. https://doi.org/10.1093/infdis/jiaa289</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Morton SU, Brodsky D. Fetal physiology and the transition to extrauterine life Clin Perinato.2016;43:395–407. doi:10.1016/j.clp.2016.04.001</mixed-citation><mixed-citation xml:lang="en">Morton SU, Brodsky D. Fetal physiology and the transition to extrauterine life Clin Perinato.2016;43:395–407. doi:10.1016/j.clp.2016.04.001</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Tsafaras GP, Ntontsi P, Xanthou G. Advantages and limitations of neonatal immune system. Front. Pediatr. 2020. Jan 28;8:5.. https:doi.org/10.3389/fped.2020.00005</mixed-citation><mixed-citation xml:lang="en">Tsafaras GP, Ntontsi P, Xanthou G. Advantages and limitations of neonatal immune system. Front. Pediatr. 2020. Jan 28;8:5.. https:doi.org/10.3389/fped.2020.00005</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Chiara F, Bartolucci GB, Mongillo M, et al. Hepatitis B vaccination at three months of age. A successful strategy? Vaccine. 2013;31(13):1696–1700. https:doi.org/10.1016/j.vaccine.2013.01.046</mixed-citation><mixed-citation xml:lang="en">Chiara F, Bartolucci GB, Mongillo M, et al. Hepatitis B vaccination at three months of age. A successful strategy? Vaccine. 2013;31(13):1696–1700. https:doi.org/10.1016/j.vaccine.2013.01.046</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Verso MG, Lo Cascio N, Noto Laddeca E, et al. Predictors of hepatitis B surface antigen titres two decades after vaccination in a cohort of students and post-graduets of the Medical School at the University of Palermo, Italy Ann. Agric Environ. Med. 2017;24:303–306. https:doi.org/10.26444/aaem/74716</mixed-citation><mixed-citation xml:lang="en">Verso MG, Lo Cascio N, Noto Laddeca E, et al. Predictors of hepatitis B surface antigen titres two decades after vaccination in a cohort of students and post-graduets of the Medical School at the University of Palermo, Italy Ann. Agric Environ. Med. 2017;24:303–306. https:doi.org/10.26444/aaem/74716</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Trevisan A, Giuliani A, Scapellato ML, et al. Sex disparity in response to hepatitis B vaccine related to the age of vaccinationю. Int. J. Environ. Res. 2020;17(1):327. https:doi.org/10.3390/jerph17010327</mixed-citation><mixed-citation xml:lang="en">Trevisan A, Giuliani A, Scapellato ML, et al. Sex disparity in response to hepatitis B vaccine related to the age of vaccinationю. Int. J. Environ. Res. 2020;17(1):327. https:doi.org/10.3390/jerph17010327</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Morris MC, Surendran N. Neonatal vaccination: Challenges and intervention strategies. Neonatology. 2016;109:161–169. https:doi.org/10.1159/000442460</mixed-citation><mixed-citation xml:lang="en">Morris MC, Surendran N. Neonatal vaccination: Challenges and intervention strategies. Neonatology. 2016;109:161–169. https:doi.org/10.1159/000442460</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Прививки. Вакцины и взрослые. Здоровье на всю жизнь. (перевод 3-го издания). Vaccinations. Vaccines and adults. Health for Life. Philadelphia. 2013:47.</mixed-citation><mixed-citation xml:lang="en">Vaccinations. Vaccines and adults. Health for life. The Children Hospital of Philadelphia. Vaccine Education Center. 2013:47 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Fischer J, Ung N, Robinson N, et al. Sex differences in immune responses to infectious diseases. Infection. 2015;43(4):399–403. https:doi.org/10.1007/s15010-015-0791-9</mixed-citation><mixed-citation xml:lang="en">Fischer J, Ung N, Robinson N, et al. Sex differences in immune responses to infectious diseases. Infection. 2015;43(4):399–403. https:doi.org/10.1007/s15010-015-0791-9</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccines. 2008;26:3551–3555. https:doi.org/10.1016/j.vaccine.2008.04.054</mixed-citation><mixed-citation xml:lang="en">Cook IF. Sexual dimorphism of humoral immunity with human vaccines. Vaccines. 2008;26:3551–3555. https:doi.org/10.1016/j.vaccine.2008.04.054</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002;347(21):1652–1661. DOI:10.1056/NEJMoa011915</mixed-citation><mixed-citation xml:lang="en">Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 2002;347(21):1652–1661. DOI:10.1056/NEJMoa011915</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet inf dis 2010;10(5):338–349. https:doi.org/10.1016/S1473-3099(10)70049-9;</mixed-citation><mixed-citation xml:lang="en">Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet inf dis 2010;10(5):338–349. https:doi.org/10.1016/S1473-3099(10)70049-9;</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Robert-Guroff M. Immunologic correlates of sexual dimorphism in human and simian immunodeficiency virus vaccine efficacy. Future virology. 2018;13(12):editorial. https:doi.org/10.2217/fvl-2018-0179</mixed-citation><mixed-citation xml:lang="en">Robert-Guroff M. Immunologic correlates of sexual dimorphism in human and simian immunodeficiency virus vaccine efficacy. Future virology. 2018;13(12):editorial. https:doi.org/10.2217/fvl-2018-0179</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Klein S, Morgan R. The impact of sex and gender on immunotherapy outcomes Biology of sex differences 2020;11:24. https:doi.org/10.1186s13293-029-00301-y</mixed-citation><mixed-citation xml:lang="en">Klein S, Morgan R. The impact of sex and gender on immunotherapy outcomes Biology of sex differences 2020;11:24. https:doi.org/10.1186 s13293-029-00301-y</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Voysey M, Barker ChIS, Snape MD, et al. Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells Vaccine 2016;34:1657–1664. https:doi.org/10.1016/j.vaccine.2016.02.036</mixed-citation><mixed-citation xml:lang="en">Voysey M, Barker ChIS, Snape MD, et al. Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells Vaccine 2016;34:1657–1664. https:doi.org/10.1016/j.vaccine.2016.02.036</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination PNAS. 2013;111(2):869–874. https:doi.org/10.1073/pnas.1321060111</mixed-citation><mixed-citation xml:lang="en">Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination PNAS. 2013;111(2):869–874. https:doi.org/10.1073/pnas.1321060111</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, et al. Sex differences in invasive pneumococcal diseases and the impact of pneumococcal conjugate vaccination in the Netherlands. 2004 to 2015. Euro Surveillance. 2017;22(10):30481. https:doi.org/10.2807/1560-7917.ES.2017.22.10.30481</mixed-citation><mixed-citation xml:lang="en">Wagenvoort GHJ, Sanders EAM, Vlaminckx BJ, et al. Sex differences in invasive pneumococcal diseases and the impact of pneumococcal conjugate vaccination in the Netherlands. 2004 to 2015. Euro Surveillance. 2017;22(10):30481. https:doi.org/10.2807/1560-7917.ES.2017.22.10.30481</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Ann. Rev. Cell Dev. Biol.2017;33:577–599. https:doi.org/10.1146/annurev-cellbio-100616-060718</mixed-citation><mixed-citation xml:lang="en">Flanagan KL, Fink AL, Plebanski M, et al. Sex and gender differences in the outcomes of vaccination over the life course. Ann. Rev. Cell Dev. Biol.2017;33:577–599. https:doi.org/10.1146/annurev-cellbio-100616-060718</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Klein SL, Flanagan KL. Sex differences in immune responses. Nat. Rev. Immunol. 2016;16(10):626–638. https:doi.org/10.1038/nri.2016.90</mixed-citation><mixed-citation xml:lang="en">Klein SL, Flanagan KL. Sex differences in immune responses. Nat. Rev. Immunol. 2016;16(10):626–638. https:doi.org/10.1038/nri.2016.90</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ruggieri A, Malorni W, Ricciardi W. Gender disparity in response to anti-viral vaccines: new clues toward personalized vaccinology. Ital J Gender Med. 2016;2(3):93–98. http:dx.doi.org/10.1723/2625.26991</mixed-citation><mixed-citation xml:lang="en">Ruggieri A, Malorni W, Ricciardi W. Gender disparity in response to anti-viral vaccines: new clues toward personalized vaccinology. Ital J Gender Med. 2016;2(3):93–98. http:dx.doi.org/10.1723/2625.26991</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Kadel S, Kovats S. Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front Immunol. 2018; Jul 20;9:1653. https: doi.org/10.3389/fimmu.2018.01653</mixed-citation><mixed-citation xml:lang="en">Kadel S, Kovats S. Sex hormones regulate innate immune cells and promote sex differences in respiratory virus infection. Front Immunol. 2018; Jul 20;9:1653. https:doi.org/10.3389/fimmu.2018.01653</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Douling DK, Mancell E. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clinical and translation immunology. 2016 May 20;5(5):e85. https: doi.org/10.1038/cti.2016.22</mixed-citation><mixed-citation xml:lang="en">Douling DK, Mancell E. Toll-like receptors: the swiss army knife of immunity and vaccine development. Clinical and translation immunology. 2016 May 20;5(5):e85. https:doi.org/10.1038/cti.2016.22</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Aaby P, Benn CS, Flanagan KL, et al. The non-specific and sex-differential effects of vaccines. Nature Reviews Immunology. 2020;20:464–470. https: doi.org/10.1038/s41577-020-0338-x</mixed-citation><mixed-citation xml:lang="en">Aaby P, Benn CS, Flanagan KL, et al. The non-specific and sex-differential effects of vaccines. Nature Reviews Immunology. 2020;20:464–470. https:doi.org/10.1038/s41577-020-0338-x</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Rechtien A, Altfeld M. Sexual dimorphism in HIV-1 infection. Semin. Immunopathol. 2018. doi:10.1007/s00281-018-0704-y</mixed-citation><mixed-citation xml:lang="en">Rechtien A, Altfeld M. Sexual dimorphism in HIV-1 infection. Semin. Immunopathol. 2018. doi:10.1007/s00281-018-0704-y</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Trigunaite AR, Dimo J, Jǿrgensen TN, et al. Suppressive effects of androgens on the immune system. Cell. Immunology 2015;294(2):87–94. https:doi.org/10.1016/j.cellimm.2015.02.004</mixed-citation><mixed-citation xml:lang="en">Trigunaite AR, Dimo J, Jǿrgensen TN, et al. Suppressive effects of androgens on the immune system. Cell. Immunology 2015;294(2):87–94. https:doi.org/10.1016/j.cellimm.2015.02.004</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Waller LA, McGregor AJ. Sex and gender specific observations and implications for COVID-19. West J Emerg Med.2020;21;507–509, https:dx.doi.org/10.5811/westjem.2020.4.47536</mixed-citation><mixed-citation xml:lang="en">Waller LA, McGregor AJ. Sex and gender specific observations and implications for COVID-19. West J Emerg Med.2020;21;507–509, https:dx.doi.org/10.5811/westjem.2020.4.47536</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Taneja V. Sex hormones determine immune response. Front Immunol.2018;9:1931. https:doi.org/10.3389/fimmu.2018.01.1931</mixed-citation><mixed-citation xml:lang="en">Taneja V. Sex hormones determine immune response. Front Immunol.2018;9:1931. https:doi.org/10.3389/fimmu.2018.01.1931</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Beadley KW, Gockel CM Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol. Med. Microbiol. 2003;38:13–22. https:doi.org/10.1016/S0928-8244(03)00202-5</mixed-citation><mixed-citation xml:lang="en">Beadley KW, Gockel CM Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone. FEMS Immunol. Med. Microbiol. 2003;38:13–22. https: doi.org/10.1016/S0928-8244(03)00202-5</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Voigt EA, Ovsyannikova IG, Schaid DJ, et al. Sex differences in older adults immune responses to seasonal influenza vaccination. Frontiers in immunology. Vaccines and molecular therapeutics. https:doi.org/10.3389/fimmu.2019.00180</mixed-citation><mixed-citation xml:lang="en">Voigt EA, Ovsyannikova IG, Schaid DJ, et al. Sex differences in older adults immune responses to seasonal influenza vaccination. Frontiers in immunology. Vaccines and molecular therapeutics. https:doi.org/10.3389/fimmu.2019.00180</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Sankaran-Walters S, Macal M, Grishina I, et al. Sex differences matter in the gut: effect on mucosal immune activation and inflammation. Biol. Sex Differ. 2013;4(1):1–12. https:doi.org/10.1186/2042-6410-4-10</mixed-citation><mixed-citation xml:lang="en">Sankaran-Walters S, Macal M, Grishina I, et al. Sex differences matter in the gut: effect on mucosal immune activation and inflammation. Biol. Sex Differ. 2013;4(1):1–12. https:doi.org/10.1186/2042-6410-4-10</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Fragiadakis GK, Bjornson-Hooper ZB, Madhireddy D, et al. Variation of immune cell responses in humans reveals sex-specific coordinated signaling across cell types. https:doi.org/10.1101/567784</mixed-citation><mixed-citation xml:lang="en">Fragiadakis GK, Bjornson-Hooper ZB, Madhireddy D, et al. Variation of immune cell responses in humans reveals sex-specific coordinated signaling across cell types. https:doi.org/10.1101/567784</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Grgelak L, Velay A, Madek Y, et al. Sex differences in the decline in the neutralizing antibodies to SARS-CoV-2. medRXiv BMJ Yale. https:doi.org/10.1101/2020.11.12.20230466</mixed-citation><mixed-citation xml:lang="en">Grgelak L, Velay A, Madek Y, et al. Sex differences in the decline in the neutralizing antibodies to SARS-CoV-2. medRXiv BMJ Yale. https:doi.org/10.1101/2020.11.12.20230466</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Engler RJ, Nelson MR, Klote MM, et al. Half-vs full dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405–2414. doi:10.1001/archinternmed.2008.513</mixed-citation><mixed-citation xml:lang="en">Engler RJ, Nelson MR, Klote MM, et al. Half-vs full dose trivalent inactivated influenza vaccine (2004–2005): age, dose, and sex effects on immune responses. Arch Intern Med. 2008;168(22):2405–2414. doi:10.1001/archinternmed.2008.513</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29. https: doi.org/10.1186/s13293-020-00304-09</mixed-citation><mixed-citation xml:lang="en">Gebhard C, Regitz-Zagrosek V, Neuhauser HK, et al. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11:29. https:doi.org/10.1186/s13293-020-00304-09</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Fathi A, Addo MM, Dahlke Ch. Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens. Front Immunol. 2020;11:601170. doi:10.3389/fimmu.2020.601170</mixed-citation><mixed-citation xml:lang="en">Fathi A, Addo MM, Dahlke Ch. Sex differences in immunity: implications for the development of novel vaccines against emerging pathogens. Front Immunol. 2020;11:601170. doi:10.3389/fimmu.2020.601170</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. J.Immun. 2020;53(3):487–495. https:doi.org/10.1016/j.immuni.2020.08.003</mixed-citation><mixed-citation xml:lang="en">Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. J.Immun. 2020;53(3):487–495. https:doi.org/10.1016/j.immuni.2020.08.003</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Duffy D. Milieu interieur: Defining the boundaries of a healthy immune response for improved vaccination strategies. Human vaccines &amp; immunotherapeutics. 2018;14(9):2217–2221. https:doi.org/10.1080/21645515.2018.1466764</mixed-citation><mixed-citation xml:lang="en">Duffy D. Milieu interieur: Defining the boundaries of a healthy immune response for improved vaccination strategies. Human vaccines &amp; immunotherapeutics. 2018;14(9):2217–2221. https:doi.org/10.1080/21645515.2018.1466764</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Klein SL, Schiebinger L, Stefanick ML, et al. Opinion: Sex inclusion in basic research drives discovery. PNAS 2015;112(17):5257–5258. https:doi.org/10.1073/pnas.1502843112</mixed-citation><mixed-citation xml:lang="en">Klein SL, Schiebinger L, Stefanick ML, et al. Opinion: Sex inclusion in basic research drives discovery. PNAS 2015;112(17):5257–5258. https:doi.org/10.1073/pnas.1502843112</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Brotman RM, Ravel J, Bavoil PM, et al. Microbiome, sex hormones, and immune responses in the reproductive tract. Challenges for vaccine development against sexually transmitted infections. Vaccine. 2014;32:1543–1552. https:doi.org/10.1016/j.vaccine.2013.10.010</mixed-citation><mixed-citation xml:lang="en">Brotman RM, Ravel J, Bavoil PM, et al. Microbiome, sex hormones, and immune responses in the reproductive tract. Challenges for vaccine development against sexually transmitted infections. Vaccine. 2014;32:1543–1552. https:doi.org/10.1016/j.vaccine.2013.10.010</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Kozlowski PA, Williams SB, Lynch RM, et al. Differential induction of mucosal and systemic antibody responses in woman after nasal, rectal, vaginal immunization influence of the menstrual cycle. J. Immunol. 2002;169:566–574. https:doi.org/10.4049/jimmunol.169.1.566</mixed-citation><mixed-citation xml:lang="en">Kozlowski PA, Williams SB, Lynch RM, et al. Differential induction of mucosal and systemic antibody responses in woman after nasal, rectal, vaginal immunization influence of the menstrual cycle. J. Immunol. 2002;169:566–574. https:doi.org/10.4049/jimmunol.169.1.566</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Lorenz TK, Demas GE, Heiman Jr. Interaction of menstrual cycle phase and sexual activity predicts mucosal and systemic humoral immunity in healthy women. Physiology &amp; Behavior 2015;152:92–98. https:doi.org/10.1016/j.physbeh.2015.09.018</mixed-citation><mixed-citation xml:lang="en">Lorenz TK, Demas GE, Heiman Jr. Interaction of menstrual cycle phase and sexual activity predicts mucosal and systemic humoral immunity in healthy women. Physiology &amp; Behavior 2015;152:92–98. https:doi.org/10.1016/j.physbeh.2015.09.018</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Giefing-Kröll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell, 2015;14(3):309–321. https:doi.org/10.1111/acel.12326</mixed-citation><mixed-citation xml:lang="en">Giefing-Kröll C, Berger P, Lepperdinger G, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell, 2015;14(3):309–321. https:doi.org/10.1111/acel.12326</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nature Reviews Immunology. 2020;20:442–447. https:doi.org/10.1038/s41577-020-0348-8</mixed-citation><mixed-citation xml:lang="en">Scully EP, Haverfield J, Ursin RL, et al. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nature Reviews Immunology. 2020;20:442–447. https:doi.org/10.1038/s41577-020-0348-8</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671–681. https:doi.org/10.1016/S0140-6736(21)00234-8</mixed-citation><mixed-citation xml:lang="en">Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021;397(10275):671–681. https:doi.org/10.1016/S0140-6736(21)00234-8</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Jones I, Roy P Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 2021;397(10275):642–643. https:doi.org/10.1016/S0140-6736(21)00191-4</mixed-citation><mixed-citation xml:lang="en">Jones I, Roy P Sputnik V COVID-19 vaccine candidate appears safe and effective. Lancet 2021;397(10275):642–643. https:doi.org/10.1016/S0140-6736(21)00191-4</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. https:doi.org/10.1101/2021.03.16.21253686</mixed-citation><mixed-citation xml:lang="en">Yelin I, Katz R, Herzel E, et al. Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. https:doi.org/10.1101/2021.03.16.21253686</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Li AJ, Li X, Sex-dependent immune response and lethality of COVID-19 Stem Cell Res. 2021;50:102116. https: doi.10.1016/j.scr.2020.102116 PMCID: PMC7837330 PMID:33352531</mixed-citation><mixed-citation xml:lang="en">Li AJ, Li X, Sex-dependent immune response and lethality of COVID-19 Stem Cell Res. 2021;50:102116. https: doi.10.1016/j.scr.2020.102116 PMCID: PMC7837330 PMID:33352531</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Jabal KA, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro surveillance 2021;26(6). https:doi.org/10.2807/1560-7917.ES.2021.26.6.2100096</mixed-citation><mixed-citation xml:lang="en">Jabal KA, Ben-Amram H, Beiruti K, et al. Impact of age, ethnicity, sex and prior infection on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro surveillance 2021;26(6). https:doi.org/10.2807/1560-7917.ES.2021.26.6.2100096</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Lumley SF, Wei J, O’Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021Aug 2;73(3):e699-e709. https:doi.org/10.1093/cid/ciab004</mixed-citation><mixed-citation xml:lang="en">Lumley SF, Wei J, O’Donnell D, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021Aug 2;73(3):e699-e709. https:doi.org/10.1093/cid/ciab004</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 2 infection rates than antibody negative healthcare workers? Large multicentre prospective cohort study (the SIREN study), England: 4 June to November 2020. medRxi BMJ Yale. https:doi.org/10.1101/2021.01.13.21249642</mixed-citation><mixed-citation xml:lang="en">Hall V, Foulkes S, Charlett A, et al. Do antibody positive healthcare workers have lower SARS-CoV-2 2 infection rates than antibody negative healthcare workers? Large multicentre prospective cohort study (the SIREN study), England: 4 June to November 2020. medRxi BMJ Yale. https:doi.org/10.1101/2021.01.13.21249642</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Roeker LE, Knor DA, Thompson MC, et al. Efficacy of the Vaccine in Patients with Chronic Lymphocytic Leukemia. Leukemia.2021;5808.Accesses54. https:doi.org/10.1182/blood.2021011568</mixed-citation><mixed-citation xml:lang="en">Roeker LE, Knor DA, Thompson MC, et al. Efficacy of the Vaccine in Patients with Chronic Lymphocytic Leukemia. Leukemia.2021;5808. Accesses54. https:doi.org/10.1182/blood.2021011568</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Herishanu Y, Avivi I, Aharon, A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. https:doi.org/10.1182/blood.2021011568</mixed-citation><mixed-citation xml:lang="en">Herishanu Y, Avivi I, Aharon, A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–3173. https:doi.org/10.1182/blood.2021011568</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Rubin LG, Levin MJ, Ljungman P, et al. IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. C58lin infect dis. 2014;58(3):309–318. https:doi.org/10.1093/cid/cit816</mixed-citation><mixed-citation xml:lang="en">Rubin LG, Levin MJ, Ljungman P, et al. IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host. C58lin infect dis. 2014;58(3):309–318. https:doi.org/10.1093/cid/cit816</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Monin IL, Laing AG, Muñoz MM, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncology 2021;22(22):765–778. https:doi.org/10.1016/S1470-2045(21)00213-8</mixed-citation><mixed-citation xml:lang="en">Monin IL, Laing AG, Muñoz MM, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncology 2021;22(22):765–778. https:doi.org/10.1016/S1470-2045(21)00213-8</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Rahimi G, Rahimi B, Panahi M, et al. An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses International Immunopharmacology. 2021;92:107365. https:doi.org/10.1016/j.intimp.2021.107365</mixed-citation><mixed-citation xml:lang="en">Rahimi G, Rahimi B, Panahi M, et al. An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses International Immunopharmacology. 2021;92:107365. https:doi.org/10.1016/j.intimp.2021.107365</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">ECDC scientific advice on seasonal influenza vaccination of children and pregnant women. ECGC Technical report European Centre for Disease Prevention and Control. Stockholm. ECDC.2012;68.</mixed-citation><mixed-citation xml:lang="en">ECDC scientific advice on seasonal influenza vaccination of children and pregnant women. ECGC Technical report European Centre for Disease Prevention and Control. Stockholm. ECDC.2012;68</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Черданцев А. П, Костинов М. П, Кусельман А. И. Вакцинация беременных против гриппа и других инфекционных заболеваний. Руководство для врачей.3-е издание. Москва. «Группа МДВ» «Карнавал Стайл».2018. 143 С.</mixed-citation><mixed-citation xml:lang="en">Cherdantsev AP, Kostinov MP, Kusel’man AI. Vaktsinatsiya beremennykh protiv grippa i drugikh infektsionnykh zabolevaniy. Rukovodstvo dlya vrachey. 3-ye izdaniye. Moskow. «Gruppa MDV», «Karnaval Stayl». 2018; 143 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Klein SL,Creisher PS, Burd I. COVID-19 vaccine testing in pregnant females is necessary. J. Clin. Invest. 2021;131(5):e147553. https:doi.org/10.1172/JCI147553</mixed-citation><mixed-citation xml:lang="en">Klein SL,Creisher PS, Burd I. COVID-19 vaccine testing in pregnant females is necessary. J. Clin. Invest. 2021;131(5):e147553. https:doi.org/10.1172/JCI147553</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Sadarangani M, Raya BA, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine.2021;39(15):2020–2023. https:doi.org/10.1016/j.vaccine.2021.03.020</mixed-citation><mixed-citation xml:lang="en">Sadarangani M, Raya BA, Conway JM, et al. Importance of COVID-19 vaccine efficacy in older age groups. Vaccine.2021;39(15):2020–2023. https:doi.org/10.1016/j.vaccine.2021.03.020</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Salvagno GL, Henry BM, Piazza G, et al. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2. Vaccination.2021 May 4;11(5):832. doi:10.3390/diagnostics11050832.</mixed-citation><mixed-citation xml:lang="en">Salvagno GL, Henry BM, Piazza G, et al. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2. Vaccination.2021 May 4;11(5):832. doi:10.3390/diagnostics11050832.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Pellini R, Venuti A, Pimpinelli F, et al. Obesity may hamper SARS-CoV-2 vaccine immunogenicity. https:doi.org/10.1101/2021.02.24.21251664</mixed-citation><mixed-citation xml:lang="en">Pellini R, Venuti A, Pimpinelli F, et al. Obesity may hamper SARS-CoV-2 vaccine immunogenicity. https:doi.org/10.1101/2021.02.24.21251664</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021;371(6532):916–921 doi:10.1126/science.abe6959</mixed-citation><mixed-citation xml:lang="en">Bubar KM, Reinholt K, Kissler SM, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021;371(6532):916–921 doi:10.1126/science.abe6959</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Bajaj V, Gadi N, Spihlman AP, et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol.2021;11:571416. Publ: 12 Jan 2021 https:doi:10.3389/fphys.2020.571416</mixed-citation><mixed-citation xml:lang="en">Bajaj V, Gadi N, Spihlman AP, et al. Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? Front. Physiol.2021;11:571416. Publ: 12 Jan 2021 https:doi:10.3389/fphys.2020.571416</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Lundberg L, Bygdell M, GS, et al. Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study. Vaccine Available online 22 June 2021. in press. https:doi.org/10.1016/j.vaccine.2021.06.045</mixed-citation><mixed-citation xml:lang="en">Lundberg L, Bygdell M, GS, et al. Recent MMR vaccination in health care workers and Covid-19: A test negative case-control study. Vaccine Available online 22 June 2021. in press. https:doi.org/10.1016/j.vaccine.2021.06.045</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019;25(12):1459–1467.</mixed-citation><mixed-citation xml:lang="en">Aaby P, Benn CS. Developing the concept of beneficial non-specific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019;25(12):1459–1467</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Zimmermann P, Curtis N Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections BMG Arch Dis Childhood 2020;106(5):5–10. http:dx.doi.org/10.1136/archdischild-2020-320338</mixed-citation><mixed-citation xml:lang="en">Zimmermann P, Curtis N Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections BMG Arch Dis Childhood 2020;106(5):5–10. http:dx.doi.org/10.1136/archdischild-2020-320338</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Каральник БВ, Алимбекова БИ, Ералиева Л. Т. Коронавирусная инфекция и BCG вакцинация: факты и возможности. Эпидемиология и Вакцинопрофилактика. Москва. 2020;19(5):18–24. https:doi.org/10.31631/2073-046-2020-19-5-18-24</mixed-citation><mixed-citation xml:lang="en">Karalnik B.V., Alimbekova B.I., Eralieva L.T. Coronavirus Infection and BCG Vaccination: Facts and Possibilities. Epidemiology and Vaccinal Prevention. 2020;19(5):18–24 (In Russ.). https://doi.org/10.31631/2073-3046-2020-19-5-18-24</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2017. https:doi.org/10.1016/j.vaccine.2017.07.062</mixed-citation><mixed-citation xml:lang="en">Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: a review. Vaccine. 2017. https:doi.org/10.1016/j.vaccine.2017.07.062</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Медуницын НВ, Яковлева ТВ. Совершенствование подходов к вакцинопрофилактике. Эпидемиология и Вакцинопрофилактика.2012;3:66–78.</mixed-citation><mixed-citation xml:lang="en">Medunitsyn NV, Yakovleva TV. Improving approaches to vaccine prophylaxis. Epidemiology and Vaccinal Prevention. 2012;3:66–78 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Vaccines for older adults: current practices and future opportunities. Ed. Weinberger B. In: Interdisciplinary Topics in Gerontology and Geriatrics Vol. 43 Ed. T. Fulop 2020;X+ 254. https:www.karger.com/Article/Pdf/511782</mixed-citation><mixed-citation xml:lang="en">Vaccines for older adults: current practices and future opportunities. Ed. Weinberger B. In: Interdisciplinary Topics in Gerontology and Geriatrics Vol. 43 Ed. T. Fulop 2020;X+ 254. https:www.karger.com/Article/Pdf/511782</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Перфильева ЮВ, Каральник БВ, Остапчук ЕО, и др. Возрастное снижение эффективности вакцинации: потенциальная роль миелоидных супрессорных клеток. Успехи геронтологии. Санкт-Петербург. 2020;33(4):785–795.</mixed-citation><mixed-citation xml:lang="en">Perfilieva SV, Karalnik BV, Ostapchuk EO, et al. Age-related decline in vaccine efficacy: the potential role of myeloid suppressor cells. Advances in Gerontology. St. Petersburg. 2020;33(4):785–795 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. Ann Intern Med.1995;123:518–527. https:doi.org/10.7326/0003-4819-123-7-199510010-00008</mixed-citation><mixed-citation xml:lang="en">Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. Ann Intern Med.1995;123:518–527. https:doi.org/10.7326/0003-4819-123-7-199510010-00008</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Grubeck-Loebenstein B. Fading immune protection in old age: vaccination in the elderly. J. Comp. Pathol. 2010;142(Suppl 1):S116–S119. https:doi.org/10.1016/j.jcpa.2009.10.002</mixed-citation><mixed-citation xml:lang="en">Grubeck-Loebenstein B. Fading immune protection in old age: vaccination in the elderly. J. Comp. Pathol. 2010;142(Suppl 1):S116–S119. https:doi.org/10.1016/j.jcpa.2009.10.002</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Long JE, Drayson MI, Taylor AE, et al. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomized trial. Vaccine. 2016;34:2679–2685. https:dx.doi.org10.1016/j.vaccine.2016.04.032</mixed-citation><mixed-citation xml:lang="en">Long JE, Drayson MI, Taylor AE, et al. Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomized trial. Vaccine. 2016;34:2679–2685. https:dx.doi.org10.1016/j.vaccine.2016.04.032</mixed-citation></citation-alternatives></ref><ref id="cit95"><label>95</label><citation-alternatives><mixed-citation xml:lang="ru">Curtis AM, Fagundes CT, Yang G, et al. Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. PNAS 2015;112(23):7231–7236. https:doi.org/10.1073/pnas.1501327112</mixed-citation><mixed-citation xml:lang="en">Curtis AM, Fagundes CT, Yang G, et al. Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1. PNAS 2015;112(23):7231–7236. https:doi.org/10.1073/pnas.1501327112</mixed-citation></citation-alternatives></ref><ref id="cit96"><label>96</label><citation-alternatives><mixed-citation xml:lang="ru">Ruiz FS, Rosa DS, Zimberg IZ, et al. Night shift work and immune response to the meningococcal conjugate vaccine in healthy workers: a proof of concept study. Sleep Medicine. 2020:263–275. https:doi.org/10.1016/j.sleep.2020.05.032</mixed-citation><mixed-citation xml:lang="en">Ruiz FS, Rosa DS, Zimberg IZ, et al. Night shift work and immune response to the meningococcal conjugate vaccine in healthy workers: a proof of concept study. Sleep Medicine. 2020:263–275. https:doi.org/10.1016/j.sleep.2020.05.032</mixed-citation></citation-alternatives></ref><ref id="cit97"><label>97</label><citation-alternatives><mixed-citation xml:lang="ru">Dhakal S, Klein SL, Coyne CB Host factors impact vaccine efficacy: implications for seasonal and universal Influenza vaccine programs. J. Virol. 2019 Oct 15;93(21):e00797–19. https:doi.org/10.1128/JVI.00797-19</mixed-citation><mixed-citation xml:lang="en">Dhakal S, Klein SL, Coyne CB. Host factors impact vaccine efficacy: implications for seasonal and universal Influenza vaccine programs. J. Virol. 2019 Oct 15;93(21):e00797–19. https:doi.org/10.1128/JVI.00797-19</mixed-citation></citation-alternatives></ref><ref id="cit98"><label>98</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit99"><label>99</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref><ref id="cit100"><label>100</label><citation-alternatives><mixed-citation xml:lang="ru"></mixed-citation><mixed-citation xml:lang="en"></mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
